Global Tetanus Human Monoclonal Antibody Market Size, Share and Trends Analysis Report, By Product Type (Light Chain Antibodies, Heavy Chain Antibodies, Mouse Antibodies, Goat Antibodies, and Others), By End User (Medical and Research Activities), Forecast (2022-2028)

The global tetanus human monoclonal antibody market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Tetanus is an acute infectious disease caused by the tetanus bacterium clostridium tetani, which enters the body through skin wounds or tissue damage such as trauma, burns, rabies II/III exposure, and traffic accidents among others. The major factor expected to drive the market growth is the significant prevalence and incidence of tetanus. In addition, advantages offered by monoclonal bodies in passive immunization is easier prediction of safety compared to vaccines, and more rapid action than vaccines. Moreover, the rise in awareness about children’s health, and increase in healthcare expenditure along with increased funding in R&D for the development of monoclonal antibodies are expected to propel the growth of the market during the forecast period.

Some major players in the market include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., and Abcam plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2021, Trinomab Biotechnology Co., Ltd. announced that the company made new progress for new product development, which is the domestically developed human monoclonal antibody against tetanus toxin TNM002. It has been officially approved by Therapeutic Goods Administration (TGA) and Human Research Ethics Committee (HREC) in Australia for the Phase I clinical trial. Further, the company added that it is the world’s first human monoclonal antibody against tetanus toxin that started the human clinical trial.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Product Type
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

• Competitive Landscape- Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., and Abcam plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tetanus Human Monoclonal Antibody Market Report by Segment

By Product Type

• Light Chain Antibodies
• Heavy Chain Antibodies
• Mouse Antibodies
• Goat Antibodies
• Others

By End User

• Medical
• Research Activities

Global Tetanus Human Monoclonal Antibody Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa